Drug intelligence / Profile preview

CT901

Development stage: Preclinical
Lead developer: Alpha Biopharma (Jiangsu) Co., Ltd.
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

CT901 is an mRNA-based therapeutic encapsulated in lipid nanoparticles (LNP) being developed by Alpha Biopharma. It is currently in development for the treatment of solid tumors, specifically osteosarcoma (OS) and hepatocellular carcinoma (HCC). As an mRNA-LNP therapy, it functions by delivering genetic instructions to cells to produce specific proteins that elicit an anti-tumor response. While the specific molecular target has not been publicly disclosed in the provided pipeline documentation, the drug represents a key part of Alpha Biopharma's advanced RNA-based oncology portfolio.

Beyond the preview

Go deeper on CT901.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT901.

Explore the full profile